公开(公告)号：US20240165079A1

公开(公告)日：2024-05-23

申请号：US18339174

申请日：2023-06-21

Applicant: Consejo Superior de Investigaciones Científicas (CSIC) ,  Universidad Autónoma de Madrid ,  CENTRO DE INVESTIGATIÓN BIOMÉDICA EN RED DE ENFERMEDADES NEURODEGENERATIVAS ,  Terran Biosciences Inc. ,  Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Inventor： Ana Maria Perez Castillo ,  Jordi Riba Serrano ,  Jose Angel Morales Garcia

IPC: A61K31/4045 ,  A61K31/496 ,  A61K31/498 ,  A61K31/519 ,  A61P25/16

CPC classification number: A61K31/4045 ,  A61K31/496 ,  A61K31/498 ,  A61K31/519 ,  A61P25/16

Abstract: The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound.

公开(公告)号：US20230146568A1

公开(公告)日：2023-05-11

申请号：US17941925

申请日：2022-09-09

Applicant: UNIVERSIDAD AUTÓNOMA DE MADRID ,  IMDEA ALIMENTACION ,  HOSPITAL UNIVERSITARIO INFANTA SOFIA

Inventor： Carlos TORRES OLIVARES ,  Luis VÁZQUEZ DE FRUTOS ,  Marta CORZO ,  Pablo ARRANZ ,  Ana RAMÍREZ DE MOLINA ,  Guillermo REGLERO RADA ,  Viviana LORIA KOHEN ,  Marta GÓMEZ DE CEDRÓN ,  Juan MORENO RUBIO ,  José Moisés LAPARRA LLOPIS ,  Enrique CASADO SÁENZ

IPC: A23L33/105 ,  A61K36/53 ,  A61K47/44 ,  A61K47/14 ,  A61K9/00 ,  A61K47/10 ,  A61K9/08 ,  A61K47/46 ,  A23L33/115 ,  A61P13/12 ,  A61P35/00 ,  A61K35/60

CPC classification number: A23L33/105 ,  A61K36/53 ,  A61K47/44 ,  A61K47/14 ,  A61K9/0014 ,  A61K47/10 ,  A61K9/08 ,  A61K9/0053 ,  A61K47/46 ,  A23L33/115 ,  A61P13/12 ,  A61P35/00 ,  A61K35/60

Abstract: The present invention relates to a lipid system which not only improves stability during digestion and oral bioavailability of various bioactive compounds in a safe and effective manner, but also in many cases enhances the effects of said compounds. The present invention also relates to formulations or compositions comprising lipid systems carrying bioactive compounds for use as immunotherapy potentiators or adjuvants for patients with cancer or immunological disorders.

公开(公告)号：US10907135B2

公开(公告)日：2021-02-02

申请号：US16083165

申请日：2016-12-30

Applicant: CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.) ,  CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS ,  UNIVERSIDAD AUTÓNOMA DE MADRID

Inventor： Juan Miguel Redondo Moya ,  Nerea Méndez-Barbero ,  Jorge Oller Pedrosa ,  Miguel Ramón Campanero García

IPC: G01N33/68 ,  C12N9/02

Abstract: The present invention refers to an In vitro method for screening for subjects at risk of developing thoracic aortic aneurysm (TAA) or a disease causing TAA comprising: (a) measuring the expression pattern or level of at least A Disintegrin And Metalloproteinase with Thrombospondin Motifs 1 (ADAMTS1) obtained from an isolated biological sample of the subjects to be screened; and (b) comparing said expression pattern or level of at least ADAMTS1 of the subjects to be screened with an already established expression pattern or level, wherein reduced expression of at least ADAMTS1 is indicative of a thoracic aortic aneurysm (TAA).

公开(公告)号：US20200270310A1

公开(公告)日：2020-08-27

申请号：US16647368

申请日：2018-07-04

Applicant: FUNDACÓIN PARA LA INVESTIGACIÓN BIOMÉDICA DEL HOSPITAL UNIVERSITARIO LA PAZ (F1BHULP) ,  FUNDACÓIN PARA LA INVESTIGACIÓN BIOMÉDICA DEL HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL (FIBIOHRC) ,  FUNDACÓIN PARA LA INVESTIGACIÓN BIOMÉDICA DEL HOSPITAL UNIVERSITARIO LA PRINCESA ,  UNIVERSIDAD AUTÓNOMA DE MADRID

Inventor： Inmaculada IBÁÑEZ DE CÁCERES ,  Javier DE CASTRO CARPEÑO ,  Olga VERA PUENTE ,  Olga PERNÍA ARIAS ,  Carlos RODRÍGUEZ ANTOLÍN ,  Victor Manuel GONZÁLEZ MUÑOZ ,  María Elena MARTÍN PALMA ,  Ana María SALGADO FIGUEROA ,  Rocío ROSAS ALONSO ,  Silvia SACRISTÁN LÓPEZ ,  Rafael LEÓN MARTÍNEZ ,  Patrycja MICHALSKA DZIAMA

IPC: C07K7/08 ,  C12Q1/6804

Abstract: The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to the use of a compound capable of decreasing or inhibiting, in vitro or ex vivo, the expression and/or activity of MAFG and thus increasing ROS-production and chemotherapy sensitivity, specifically in cancer cells resistant to platinum-based therapy. The present disclosure further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The compound of the invention can indeed be advantageously used, in combination with at least one chemotherapeutic dmg, for treating cancer, for preventing cancer metastasis, increasing overall survival and/or for preventing cancer recurrence in a subject. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject, as well as kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.

公开(公告)号：US20200054647A1

公开(公告)日：2020-02-20

申请号：US16348589

申请日：2017-11-10

Applicant: UNIVERSIDADE DE SANTIAGO DE COMPOSTELA ,  UNIVERSIDAD AUTÓNOMA DE MADRID

Inventor： Jessica RODRÍGUEZ VILLAR ,  José Luis MASCAREÑAS CID ,  José RODRÍGUEZ COUCEIRO ,  Jesús MOSQUERA MOSQUERA ,  Marcos Eugenio VÁZQUEZ SENTÍS ,  Bruno SAINZ ANDING

IPC: A61K31/555 ,  A61P35/00

Abstract: The present invention relates to the use of ruthenium(II) complexes for preparing a medicinal product for treating cancer, particularly cancer comprising cancer stem cells. Said ruthenium complexes are capable of selectively metallating guanine quadruplexes, thus resulting in increased expression of the c-MYC oncogene. This increase in the proportion of c-MYC may promote the differentiation of cancer stem cells.

公开(公告)号：US10532082B2

公开(公告)日：2020-01-14

申请号：US15314395

申请日：2015-05-27

Applicant: Fundació Hospital Universitari Vall d'Hebron-Institut de Recerca ,  Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz ,  Universidad Autónoma De Madrid

Inventor： Jesús Egido De Los Rios ,  Carmen Gómez Guerrero ,  Rafael Simó Canonge ,  Cristina Hernández Pascual

IPC: A61K38/17 ,  A61K9/00 ,  A61K38/10 ,  A61K47/54

Abstract: The present invention relates to a SOCS1-derived peptide for use in chronic complications of diabetes, particularly ocular, renal, nerve and vascular complications, as well as compositions containing same and isolated polynucleotides encoding same. The present invention also relates to the SOCS1-derived peptide for topical use in the treatment and/or prevention of neurodegenerative diseases of the retina, particularly in the early stages of diabetic retinopathy and other diseases of the retina in which neurodegeneration plays an essential role.

公开(公告)号：US20180037538A1

公开(公告)日：2018-02-08

申请号：US15538341

申请日：2015-12-17

Applicant: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS ,  CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES NEURODEGENERATIVAS (CIBERNED) ,  UNIVERSIDAD AUTÓNOMA DE MADRID

Inventor： MARTA GUTIÉRREZ RODRÍGUEZ ,  PILAR CERCOS PITA ,  MARÍA ROSARIO HERRANZ HERRANZ ,  MARÍA TERESA GARCÍA LÓPEZ ,  MARÍA CARMEN VALENZUELA MIRANDA ,  JOSÉ RAMÓN NARANJO ORIVIO ,  BRITT MELLSTROM ,  PAZ GONZÁLEZ PÉREZ ,  MARÍA MERCEDES MARTÍN MARTÍNEZ ,  JOSÉ MANUEL DOPAZO SANTOS

IPC: C07C233/33 ,  C07D233/64 ,  C07C233/31

CPC classification number: C07C233/33 ,  C07C233/31 ,  C07C233/55 ,  C07C235/38 ,  C07C237/42 ,  C07D233/64

Abstract: The present invention relates to a group of compounds with a structural nucleus derived from phenylacetamide, having the following formula (I): that can modulate the DREAM neuronal calcium sensor. Consequently, the present invention also relates to the use of these compounds for the treatment or prevention of disorders or diseases in which DREAM levels are above or below physiologically normal levels.

公开(公告)号：US20170209496A1

公开(公告)日：2017-07-27

申请号：US15464138

申请日：2017-03-20

Applicant: TiGenix, S.A.U. ,  Universidad Autónoma de Madrid

Inventor： María Gema FERNÁNDEZ MIGUEL ,  Manuel Ángel GONZÁLEZ DE LA PEÑA ,  Rosa Ana GARCÍA CASTRO ,  Mariano GARCÍA ARRANZ ,  Damián GARCÍA OLMO

IPC: A61K35/35 ,  A61B17/32 ,  A61K45/06 ,  A61L24/10 ,  C12N5/0775

CPC classification number: A61K35/35 ,  A61B17/1659 ,  A61B17/32 ,  A61B2017/320008 ,  A61K35/12 ,  A61K45/06 ,  A61L24/0015 ,  A61L24/106 ,  A61L27/3604 ,  A61L27/3834 ,  A61L27/3839 ,  A61L27/3869 ,  A61L27/3895 ,  A61L2300/64 ,  C12N5/0667 ,  C12N2509/00 ,  C12N2510/00 ,  C12N2533/56

Abstract: Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.

公开(公告)号：US20150374852A1

公开(公告)日：2015-12-31

申请号：US14767490

申请日：2014-02-12

Applicant: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) ,  UNIVERSIDAD AUTÓNOMA DE MADRID

Inventor： Angel Trueba Saiz ,  Ignacio Torres Aleman ,  Carmen Cavada Martinez ,  Angel Nunez Molina

IPC: A61K49/00 ,  A61K45/06 ,  A61K38/30

CPC classification number: A61K49/0004 ,  A61B5/0476 ,  A61B5/4088 ,  A61B5/4842 ,  A61B5/4848 ,  A61B2503/40 ,  A61B2503/42 ,  A61K31/5513 ,  A61K38/30 ,  A61K45/06 ,  G01N33/6896 ,  G01N2333/475 ,  G01N2800/2821 ,  A61K2300/00

Abstract: The invention relates to the use of the insulin-like growth factor (IGF-1) as a reagent for the early diagnosis and/or prognosis of Alzheimer disease, to a kit comprising IGF-1 and a sedative, and to the use thereof in the early diagnosis and/or prognosis of Alzheimer disease.

Abstract translation: 本发明涉及胰岛素样生长因子（IGF-1）作为阿尔茨海默氏病的早期诊断和/或预后的试剂用于包含IGF-1和镇静剂的试剂盒及其在 阿尔茨海默病的早期诊断和/或预后。

公开(公告)号：US12209103B2

公开(公告)日：2025-01-28

申请号：US17255121

申请日：2019-06-21

Applicant: UNIVERSIDAD AUTÓNOMA DE MADRID

Inventor： Josep Puigmarti-Luis ,  Felix Juan Zamora Abanades ,  Carlos Franco Pujante ,  David Rodriguez San Miguel ,  Alessandro Sorrenti

IPC: C07F1/08 ,  B01J35/12 ,  B01J35/27 ,  B33Y70/00 ,  C01B37/00 ,  C09D11/02 ,  B82Y30/00 ,  B82Y40/00

Abstract: The present invention relates to the field porous crystalline materials, more particularly to metal organic frameworks (MOFs) and covalent organic frameworks (COFs). According to this invention, micelles are used as nanoreactors for the synthesis and stabilisation of porous crystalline materials in aqueous dispersions. Disclosed are dispersions comprising such porous crystalline materials, the synthesis and use of such dispersions. Further disclosed are novel porous crystalline materials, the synthesis and use of such crystalline materials. Further disclosed are novel inks comprising the dispersions and non-solvent, the synthesis and use of such inks for direct printing, 2D printing and 3D printing.